The Potential Benefits of Electronic Cigarettes: A Long-term Study

Sep.05.2022
The Potential Benefits of Electronic Cigarettes: A Long-term Study
A long-term experiment shows e-cigarette usage can reduce the harm of smoking compared to traditional cigarettes.

A long-term experiment involving hundreds of smokers was conducted, in which some continued to smoke, while others switched completely to e-cigarettes, and some quit nicotine altogether. Analysis of biological markers for potential harm indicated that completely switching to e-cigarettes can reduce the harm associated with smoking.


In 1798, Dr. Benjamin Rush was one of the earliest people to suggest that smoking could lead to cancer. By the 1920s, over a thousand cases of lung cancer had been reported. Meanwhile, inventors began looking for ways to reduce the risks of tobacco. In 1927, American Joseph Robinson patented a device that produced electronic vapor and proposed the safe inhalation of vapors containing medicinal compounds without being burned. This idea remained on paper.


The modern e-cigarette did not appear until 2003, when it was developed by Chinese pharmacist Hon Lik. Since then, its popularity has gradually increased. Today, lung cancer is the second most common cancer in the world, with smoking being the main cause of its development (in 85% of cases). In Russia, the incidence and mortality rates of lung cancer also rank second, causing 27,000 deaths each year.


Since 2019, the number of smokers in Russia has been declining gradually. According to VTsIOM, approximately one-third of the population in urban areas smoke, with the majority of them smoking more than a pack a day using traditional methods such as cigarettes, cigars, roll-your-own and hookah. However, there is a rapid increase in the popularity of e-cigarettes.


Electronic cigarettes entered Europe, the United States, and Russia around 2007. At that time, there were no studies on the effects of these new products on the body, and as a result, health organizations and doctors were unsure how to regulate their circulation and provide advice to people. Today, the global electronic cigarette market is valued at over $18 billion. Analysis shows that smoking not only wastes money but also has a negative impact on health. Smokers have a death rate over three times higher than non-smokers after the age of 65.


Alternative products to traditional cigarettes are becoming increasingly popular worldwide. Many have successfully quit smoking with their help. For those who are not ready or unable to quit smoking entirely, electronic cigarettes can reduce the amount of toxins inhaled. Fortunately, over the past 20 years, there have been enough medical observations and scientific studies to conclude that high-quality, verified electronic cigarettes can reduce harm to health and help overcome addiction.


One method of monitoring the effects of smoking on the body is to track exposure biomarkers (BoE) and potential harm (BoPH) associated with oxidative stress, cancer, cardiovascular disease, and respiratory illness.


A new study on biomarkers has indicated that completely switching from traditional cigarettes to alternative smoking products can significantly reduce the harm caused by smoking.


In the UK, scientists have decided to examine the changes in biomarkers of individuals who have quit smoking or switched to e-cigarettes completely over a few months. The transition to heating systems is equivalent to quitting smoking completely for some biomarkers. The results have been published in the peer-reviewed medical journal, "Internal Medicine and Emergency Medicine Journal".


The study involved adults aged 23 to 55 who had been smoking for at least 5 years and were smoking between 10-30 non-menthol cigarettes per day at the start of the study. They were all healthy. Participants who wished to continue smoking were randomly divided into two groups: one group continued to smoke regular cigarettes, while the second group was given electronic cigarettes. At the time of publication, 59 people continued to smoke, 127 people switched to electronic cigarettes, 109 people stopped smoking altogether, and 37 people were in the control group. To monitor compliance, participants were tested for CEVal biomarkers.


It is worth noting that participants who switched to e-cigarettes prior to the experiment had slightly higher consumption rates compared to traditional cigarette users (with one e-cigarette deemed equivalent to one cigarette) and those who continued smoking. However, this consumption rate remained stable throughout all six months of the study. The results indicate that switching to e-cigarettes led to statistically significant changes in biological markers, with some even approaching data from the group who quit smoking altogether. Canadian scientists have discovered that smokers and those with chronic obstructive pulmonary disease show increased entry of SARS-CoV-2 into their epithelial cells.


Biomarkers for oxidative stress in the body (8-Epi-PGF2α Type III) were significantly reduced, and white blood cell count decreased (indicating a presence of inflammation). At the same time, indicators of lung and vascular health improved, as did the level of high-density lipoprotein cholesterol, which suggests a lower risk for cardiovascular disease. Most importantly, those who switched to e-cigarettes saw a decrease of about half in NNAL levels (a lung cancer risk indicator) to 115.7 ng/day. Of course, the decrease was even greater in those who quit smoking entirely, going from smokers' levels (221.94 ng/day) to four times less (59.09 ng/day). However, in order to reach the levels of those who never smoked, the decrease must be 20 times less (to 11.54 ng/day).


It’s important to remember that there are different alternatives to traditional smoking, and they are all quite different from each other. Electronic cigarettes or e-cigarettes use a special liquid that produces thick vapor. The primary ingredients in this liquid are glycerin or propylene glycol, which are compounds used in smoke machines. Studies have shown that these ingredients do not cause lung inflammation, but they do cause dryness. The e-liquid used in e-cigarettes can contain nicotine (at varying concentrations) or it can be nicotine-free.


Nicotine has been proven to be addictive, but the main harm comes from other toxic compounds formed during the combustion of tobacco - there are about 6,000 of them. Some scientists believe that these compounds increase the risk of addiction to nicotine.


Disclaimer: 1. The content of this article is compiled from third-party information and is only for industry exchange and learning. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the content of the article. The compilation of this article is only for industry exchange and research. 3. Due to the limited level of compilation, the compiled article may not express the same meaning as the original article, please refer to the original article for accuracy. 4. For any domestic, Hong Kong, Macao, Taiwan, or foreign expressions and positions, 2FIRSTS is fully in line with the Chinese government. 5. The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
R.J. Reynolds Vapor Company has introduced Vuse Pro prefilled pods in Peach, Berry, Watermelon and Fresh Mint in selected U.S. states. Vuse’s U.S. website says the pods are intended for use with existing Vuse Alto devices. Each contains 2.0 mL of e-liquid at 5.0% nicotine by weight, uses nicotine salts and is offered in two- and four-pod packs. Reynolds said the rollout includes mandatory ID scanning for every purchase, purchase limits, stronger retailer-accountability requirements and strict age-restricted marketing standards. The four pods have not received marketing authorization from the U.S. Food and Drug Administration.
Sep.10
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives